Data / Form D filings / Genomenon, Inc.
Genomenon, Inc.: Form D filings
Genomenon, Inc., a biotechnology company in Ann Arbor, MI, filed 5 Form D notices with the SEC between 2015 and 2026. The latest, on July 30, 2026, reports $6 million sold of a $10 million offering to 30 investors.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 206 E. Huron Street Suite 114, Ann Arbor, MI, 48104
- Phone
- (734) 794-3075
- Industry
- Biotechnology
- Entity type
- Corporation
- Incorporated in
- Delaware
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 1650557
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Jul 30, 2026 | New notice | $10,000,000 | $6,025,002 | $3,974,998 | 30 | Jul 15, 2026 | sec.gov |
| May 16, 2024 | New notice | $6,000,000 | $5,461,759 | $538,241 | 30 | May 1, 2024 | sec.gov |
| Mar 10, 2022 | New notice | $19,999,994 | $19,999,994 | 23 | Feb 24, 2022 | sec.gov | |
| May 21, 2020 | New notice | $3,000,000 | $2,885,877 | $114,123 | 36 | May 15, 2020 | sec.gov |
| Aug 14, 2015 | New notice | $1,000,000 | $446,003 | $553,997 | 11 | Aug 6, 2015 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Michael Klein | Executive Officer, Director | |
| Mark Kiel | Executive Officer, Director | |
| Patricia Glaza | Director | |
| David Gregorka | Director | |
| Michael Gross | Director | |
| Brian Groark | Executive Officer | |
| Sam Globus | Executive Officer |
Other biotechnology companies in Michigan that filed recently
- Dvant Pharma, Inc. $1.2 million · Oct 13, 2026
- iReprogram, Inc offering · Aug 13, 2026
Every Form D from the week of Jul 27, 2026 · All recent filings in Michigan · All recent Biotechnology filings
Read from SEC EDGAR. Amount sold is what Genomenon, Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.